Nitric oxide-releasing NSAIDs: GI-safe antithrombotics

Area of Science:

• Pharmacology
• Gastroenterology
• Cardiology

Background:

• Aspirin is widely used for preventing myocardial infarction and stroke.
• Gastrointestinal toxicity, including bleeding and ulceration, limits aspirin's long-term use.
• Non-steroidal anti-inflammatory drugs (NSAIDs) also carry significant gastrointestinal risks.

Purpose of the Study:

• To evaluate the efficacy and safety of novel nitric oxide (NO)-releasing aspirin derivatives.
• To determine if NO-aspirin compounds can provide antithrombotic benefits with reduced gastrointestinal damage.
• To explore the potential of NO-NSAIDs as safer alternatives to conventional NSAIDs.

Main Methods:

• Synthesis and evaluation of two NO-aspirin compounds (NCX-4215 and NCX-4016).
• Assessment of anti-aggregatory activity and gastric damage in preclinical models.
• Investigation of protective effects against gastrointestinal injury and inhibition of leukocyte adherence.
• Evaluation of effects in experimental hypertension models.

Main Results:

• NO-aspirin derivatives demonstrated improved anti-platelet aggregation compared to aspirin.
• These compounds did not induce detectable gastric damage and showed protective effects against other injurious agents.
• Significant inhibition of leukocyte adherence to vascular endothelium was observed.
• NO-releasing derivatives also showed beneficial effects in experimental hypertension.

Conclusions:

• NO-releasing aspirin derivatives represent a promising class of gastrointestinal-sparing antithrombotic agents.
• These compounds offer enhanced efficacy and reduced toxicity compared to conventional aspirin.
• NO-NSAIDs hold significant potential for the prophylaxis of cardiovascular events with improved safety profiles.